A user was prescribed a topical solution containing 10% Minoxidil and 0.1% Finasteride for hair loss. They are seeking experiences with these dosage levels.
A 21-year-old male is using a Minoxidil (10%) and Finasteride (0.1%) topical solution with a Keraglo Men tablet for hair loss, experiencing positive results without side effects. He advises another user to prepare questions for a dermatologist visit and discusses potential treatment adjustments.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.
The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.
The user started using topical finasteride 0.025% and minoxidil 5% twice daily, seeing initial improvement but later experiencing shedding and scalp pain. They are considering increasing the finasteride dose to 0.05% while using keto shampoo and dermarolling, and are debating the effectiveness of low versus standard doses of finasteride.
A 20-year-old with stage 3 hair loss saw good results using Topical Min 5%, Oral Fin 1mg, DHT Blocker Shampoo, and DHT blocking and Vitamin gummy. The doctor advised stopping Fin after six months due to hormone concerns, but the user is hesitant.
A 25-year-old is using a nightly routine of topical finasteride 0.3% and minoxidil 6%, along with a derma roller and Nizoral shampoo, to address crown hair loss. The user reports no side effects and noticeable improvement over 2.5 months.
A new topical Dutasteride with 20 times better scalp absorption being developed and tested for release in 2023; use of existing drugs, such as Minoxidil and finasteride; and mesotherapy as an alternative hair loss treatment.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
The user has been using topical finasteride 0.1% for almost 7 months but is experiencing worsening hair loss and is considering adding minoxidil 5% to their regimen. They are hesitant about oral finasteride and are exploring options for topical treatments, including minoxidil and possibly dutasteride.
A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.
Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.
There is no reliable ranking for the effectiveness of topical anti-androgens like Fluridil, RU58841, and Pyrilutamide, with limited studies available. Some users suggest Pyrilutamide may be promising based on ongoing trials, while Fluridil combined with finasteride has shown positive results for some individuals.
The conversation discusses creating a 0.01% topical dutasteride solution mixed with minoxidil for hair loss treatment, with concerns about absorption and effectiveness. Some users suggest that dutasteride needs specific formulation for better absorption, while others recommend oral use for practicality.
The conversation discusses hair loss treatments, specifically the progress made with Pyrilutamide over 15 months. One person suggests using oral Minoxidil or Dutasteride, but another mentions experiencing negative side effects from oral Finasteride.
The user experienced significant hair quality and thickness improvement using a daily topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable regrowth in the last few months. Minoxidil can darken hair by increasing pigmentation.
A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.